Everything below concerns alpha-MSH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
nondisjunction The failure of homologous chromosomes or sister chromatids to segregate properly during cell division. Nondisjunction results in daughter cells that are aneuploid, containing abnormal numbers of one or more specific chromosomes. It may be caused by a variety of factors.
== Early life and background == Alexander Zverev was born on 20 April 1997 in Hamburg, Germany, to Russian parents Irina Zvereva and Alexander Zverev Sr. His older brother, Mischa, born nearly a decade earlier, was also a professional tennis player. Both of his parents were professional tennis players for the Soviet Union. His father, who ranked as high as No. 175 in the world, became the top-ranked men's player nationally, while his mother was the fourth-highest-ranked women's player in the Soviet Union. They both moved from Sochi to the capital to train at the CSKA Moscow military-run tennis club. The Soviet government often restricted their players from competing outside the country, an impediment that limited how high either of Alexander's parents could rise in the world rankings. With the collapse of the Soviet Union imminent, Irina went to Germany to compete at a tournament in 1990, with her husband accompanying as her coach. While in Germany, they were offered jobs as tennis instructors. After initially declining, they accepted an offer to work at the Uhlenhorster Hockey Club in Hamburg the following year and ended up settling in the country. Zverev, known in his family as Sascha (the Russian-language diminutive for Alexander), started playing tennis at the age of three. Since he began playing tennis at a very young age, he has said, "One day, when I was, I think, one year and five months old, I just picked up a little racket and I was starting to push the ball all over our apartment, and since then, they took me out on the court.
=== Metformin therapy === Metformin, a drug used for weight loss in diabetes patients, has been shown to reduce keto-isoaproic acid (KIC) in patient-derived fibroblasts as well as a murine model of MSUD. Metformin has also been shown to aid weight loss in MSUD patients who are at increased risk for obesity and related complications when following prescribed hyper-caloric diets to avoid metabolic decompensation.
Sources: en.wikipedia.org
=== Redox buffer in the irradiated fuel matrix === Molybdenum behaves as a redox buffer in the spent nuclear fuel matrix. 99Mo is one of the most abundant fission product, with a fission yield of 6.1% close to that of xenon (135Xe, 6.33%). Molybdenum plays a critical role in nuclear fuel chemistry because it affects the fuel's oxygen fugacity. Molybdenum produced by nuclear fission in the fuel matrix inhibits the oxidation of the uranium dioxide.
troops back in could have saved South Vietnam. On 17 April 1975, the Lon Nol regime collapsed, and the Khmer Rouge took Phnom Penh. On 20 April, Kissinger instructed Graham Martin, U.S. ambassador in Saigon, to start preparing to evacuate all Americans from the country. Kissinger further instructed Martin that no South Vietnamese were to be included in the pull out. Martin complained to Kissinger that the "only ass which isn't covered is mine", Kissinger assured him: "When this thing is finally over, I'll be hanging several yards higher than you". On 29 April, Option IV, the largest helicopter evacuation in history, began as 70 Marine helicopters flew 8,000 people from the American embassy to the fleet offshore. Later in the day, Kissinger ordered Martin to blow up the satellite terminal at the embassy, saying, "I want you heroes home". At 7:53 am, the last Marine helicopter departed from the embassy in Saigon, marking the end of the American presence in Vietnam. On 30 April 1975, Saigon fell to the PAVN, and the war in Vietnam finally ended.
R-CH=CH-CO-SCoA + H2O2 Hydrogen peroxide arises by the degradation of adenosine monophosphate, which yields hypoxanthine. Hypoxanthine is then oxidatively catabolized first to xanthine and then to uric acid, and the reaction is catalyzed by the enzyme xanthine oxidase:
Sources: en.wikipedia.org
Isomerases Rearrangements in which a hydrogen atom is directly transferred between two adjacent atoms with concomitant exchange of the second substituent, X, which may be a carbon atom with substituents, an oxygen atom of an alcohol, or an amine. These use the AdoB12 (adenosylcobalamin) form of the vitamin. Methyltransferases Methyl (–CH3) group transfers between two molecules. These use the MeB12 (methylcobalamin) form of the vitamin. Dehalogenases Some species of anaerobic bacteria synthesize B12-dependent dehalogenases, which have potential commercial applications for degrading chlorinated pollutants. The microorganisms may either be capable of de novo corrinoid biosynthesis or are dependent on exogenous vitamin B12. In humans, two major coenzyme B12-dependent enzyme families corresponding to the first two reaction types, are known. These are typified by the following two enzymes:
==== Infectious ==== Certain infections are known to cause catatonia, either by directly impairing brain function or by increasing a person's susceptibility to other diseases that can do so. HIV and AIDS can cause catatonia by predisposing one to infections in the brain, including different types of viral encephalitis. Borrelia burgdorferi causes Lyme disease, which has been shown to cause catatonia by infecting the brain and causing encephalitis.
Early attempts to create alien-human hybrids were pioneered by German and Japanese scientists shortly after World War II, and for some time during the Cold War. However, these often met with failure, and the Syndicate started to rely more on their own scientists. According to the Alien Bounty Hunter, in the 1950s, Soviet geneticists found a unique genetic anomaly within identical twins. The Colonists and Syndicate scientists used this to eventually develop human clones with alien elements and partial hybrids, but they were still ultimately inferior. Hybrids of this type include Samantha Mulder, Kurt Crawford, the Gregors, Ernest Calderon, and Dr. William Secare. Child and adult versions of Samantha and Kurt are also seen. These clones have the same caustic greenish blood of the aliens, have greater muscular strength and higher physical endurance levels than most normal humans, and can breathe underwater. In addition to their intended use by the alien colonists, the Syndicate is occasionally seen using these clones to perform various tasks, such as research and physical labor. The pinnacle of the project is Cassandra Spender (Veronica Cartwright), mother of Jeffrey Spender (Chris Owens) and ex-wife of The Smoking Man. Cassandra is a hybrid created through a process other than cloning, and worked on by both the Syndicate and the aliens themselves, although the exact methods used to transform her are never fully revealed. The experiment presumably began when she, along with other family members of the Syndicate, were turned over to the colonists in 1973.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.